M&A Deal Summary |
|
|---|---|
| Date | 2025-01-23 |
| Target | GPCR USA |
| Sector | Life Science |
| Buyer(s) | Exicure |
| Sellers(s) | GPCR Therapeutics |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2011 |
| Sector | Life Science |
| Employees | 7 |
| Revenue | 1M USD (2024) |
Exicure is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. Exicure was founded in 2011 and is based in Chicago, Illinois.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
GPCR Therapeutics, Inc. is a biotechnology company that engages in the field of GPCR heteromer science and has proprietary expertise and technology applicable to the development of this class of anti-cancer targets.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-11-24 |
Burixafor
South Korea Burixafor is an orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with receptor binding and hematopoietic stem cell-mobilization activities. |
Buy | - |
